| Title |
Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions
|
|---|---|
| Published in |
Cancer Management and Research, May 2017
|
| DOI | 10.2147/cmar.s126136 |
| Pubmed ID | |
| Authors |
Ogbonna Collins Nwabuko, Elizabeth Eneikido Igbigbi, Innocent Ijezie Chukwuonye, Martin Anazodo Nnoli |
| Abstract |
Multiple myeloma (MM) is one of the hematological malignancies that require palliative care. This is because of the life-threatening nature and the suffering associated with the illness. The aim of this study is to bring to the fore the complications experienced by people living with MM in the Niger-Delta region of Nigeria and the outcome of various palliative interventions. This was a 10-year multi-center retrospective study of 26 patients diagnosed and managed in three major centers in the Niger-Delta region of Nigeria from January 2003 to December 2012. Information on the clinical, laboratory, radiological data, and palliative treatment was obtained at presentation and subsequently at intervals of 3 months until the patient was lost to follow-up. The mean duration from onset of symptoms to diagnosis was 13.12 months (95% CI, 6.65-19.58). A total of 16 (61.5%), eight (30.8%), and two subjects (7.7%) presented in Durie-Salmon (DS) stages III, II, and I, respectively. The complications presented by patients at diagnoses included bone pain (84.6%), anemia (61.5%), nephropathy (23.1%), and hemiplegia (35%). All the patients received analgesics, while 50.0% received blood transfusion, 56.7% had surgery performed, 19% had hemodialysis, and 3.8% received radiotherapy. A total of 10 (38%) patients benefited from bisphosphonates (BPs). A total of 57.6% of patients were on melphalan-prednisone (MP) double regimen, while 19% and 8% patients were on MP-thalidomide and MP-bortezomib triple regimens, respectively. A total of 3.8% of patients at DS stage IIIB disease had autologous stem-cell transplantation (ASCT). Only 7.6% of the myeloma patients survived up to 5 years post diagnosis. The overall mean survival interval was 39.7 months (95% CI, 32.1-47.2). Late diagnosis and inadequate palliative care account for major complications encountered by MM patients in the Niger-Delta region of Nigeria. This could be responsible for the poor prognostic outcome and low survival interval of MM individuals in this region. There is, therefore, a need to improve the quality of palliative care received by myeloma patients in this region. This is achievable via provision of relevant and affordable health care facilities for diagnosis and treatment of the disease. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 67 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 16% |
| Other | 7 | 10% |
| Student > Bachelor | 7 | 10% |
| Student > Ph. D. Student | 7 | 10% |
| Student > Doctoral Student | 5 | 7% |
| Other | 8 | 12% |
| Unknown | 22 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 33% |
| Nursing and Health Professions | 8 | 12% |
| Immunology and Microbiology | 6 | 9% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Arts and Humanities | 1 | 1% |
| Other | 5 | 7% |
| Unknown | 23 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2022.
All research outputs
#6,438,708
of 23,700,294 outputs
Outputs from Cancer Management and Research
#261
of 2,018 outputs
Outputs of similar age
#99,254
of 311,964 outputs
Outputs of similar age from Cancer Management and Research
#5
of 11 outputs
Altmetric has tracked 23,700,294 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,018 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,964 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.